# A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

> **NCT01727726** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 2182 (actual)

## Conditions studied

- Depressive Disorder
- Depression
- Depressive Disorder, Major
- Mood Disorders
- Mental Disorders

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Seroquel XR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01727726
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-10-17
- **Final completion:** 2016-11-10
- **Target enrollment:** 2182 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727726, "A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01727726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*